Biogen Inc (BIIB)

$209.36 -0.47 (-0.22%)
Market Cap 31.00B
Revenue (ttm) 9.89B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 15.08
Forward PE 16.85
Profit Margin 13.07%
Debt to Equity Ratio 0.39
Volume 379,414
Avg Vol 1,234,020
Day's Range N/A - N/A
Shares Out 147.75M
Stochastic %K 63%
Beta 0.17
Analysts Strong Sell
Price Target $238.00

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
ksoption
ksoption Aug. 16 at 4:16 PM
$CBOE $PM $HON $BIIB
0 · Reply
SnowyDingo
SnowyDingo Aug. 15 at 5:43 PM
$NAGE CEO spent the earnings call seeding a takeout narrative. 4 buyer universes: 🛒 CPG (Thorne/PG $3.8B comp) → $NSRGY (Nestlé Health Science) 💄 Beauty ("2 global skincare cos") → $LRLCY (L'Oréal) 💊 Pharma (Reata/ $7.3B comp) → $BIIB, for NB4168 📱 Telehealth → $HIMS But: comp gated on $15 PSUs, so he's incentivized to talk his book. "In discussions" ≠ deal. No name, no LOI, no timeline. Real tell = a signed exclusive skincare supply deal w/ a named $LRLCY-tier buyer. Until then it's CEO optionality, not a catalyst
1 · Reply
ksoption
ksoption Aug. 15 at 1:16 AM
$NBIS $C $BIIB 🤞
0 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 2:13 PM
$PMN PT Raised to $100 at Guggenheim Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drug's efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer's. If PMN shows the potential to be safer than existing treatments $LLY $BIIB. FDA views it ethical imperative to expedite the approval process through fast-track programs. https://www.streetinsider.com/dr/news.php?id=26925256&gfv=1
0 · Reply
11thestate
11thestate Aug. 14 at 1:47 PM
There’s another $BIIB investor settlement to know about. The settlement centers on claims that Biogen misled investors about aducanumab’s clinical trial data and why the ENGAGE study failed. After FDA briefing materials raised concerns in 2020, the FDA Advisory Committee voted 10-0 against the drug’s effectiveness, and $BIIB fell 28%. This case covers purchases between 2019 and 2020. If you weren't eligible for the other Biogen case, you may want to check this one, since the class period is different and extends further back. Check if your eligible and file a claim: https://11th.com/cases/biogen-investor-settlement
0 · Reply
vjtweet
vjtweet Aug. 12 at 7:24 PM
$BIIB new long. No rush.. hold for many months.
0 · Reply
11thestate
11thestate Aug. 10 at 1:46 PM
Imagine buying $BIIB at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $BIIB investors out there, we’ve got some important news: a $18.9 million investor settlement is now open for claims from shareholders who purchased shares in 2021 The deadline is next months, you can check if you’re eligible and claim your share: https://11th.com/cases/biib-investor-settlement
0 · Reply
Fangster1
Fangster1 Aug. 9 at 7:14 PM
$BIIB $GANX $JAZZ Very good give and take to this thread. I’ll never pretend to fully understand the science but I do understand statements made by the company. IMO they have a good idea where the 270 stands. If the 270 is a known negative, I would think some level of disclosure would be necessary after the company speak. As an investor, no issue waiting for the 360. If the 360 plays out, we’re solid gold with diamond hands. We’ll see!
1 · Reply
Jwa68
Jwa68 Aug. 9 at 1:02 AM
$GANX Khalid and Gene are very wisely beginning to position Gain as a platform company, versus a single drug company, with a vast multi target franchise opportunity in neurodegeneration. With Magellan capable of generating an endless organic pipeline of additional molecules which may be advanced to the clinic, all building upon what they have learned from GT-00287. While we will never get there unfortunately, this is similar to how $BIIB (Biogen) was started way back when and trading at just a couple dollars a share, along with $JAZZ. Ironically, Gene was one of the first analysts to initiate and recommend both names in their infancy, early on on his career as an analyst.
2 · Reply
GoforProMIS
GoforProMIS Aug. 7 at 5:48 PM
$PMN $LLY $BIIB $RHHBY The real jackpot: PMN267 + PMN442 ProMIS describes three key antibody programs: PMN310 → Alzheimer's disease / Amyloid-ß oligomers => PMN310 potential $5-10 bn * PMN267 → ALS / misfolded TDP-43 => PMN267 potential $1-3 bn * PMN442 → Parkinson's disease, MSA, => PMN442 potential $1-3 bn and other synucleinopathies Other Platforms potential $0,5-2 bn means in total range from 7.5-18 bn with a potential Share price of => $405 to $970 This is not pure fantasy.
0 · Reply
Latest News on BIIB
Biogen upgraded to Outperform from Peer Perform at Wolfe Research

2026-08-17T08:29:32.000Z - 11 hours ago

Biogen upgraded to Outperform from Peer Perform at Wolfe Research

Wolfe upgrades Biogen to Outperform on late-stage pipeline

2026-08-17T08:28:42.000Z - 11 hours ago

Wolfe upgrades Biogen to Outperform on late-stage pipeline

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 3 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN GILD JNJ LLY MRK UNH

Biogen completes acquisition of RayThera

2026-08-06T22:55:34.000Z - 10 days ago

Biogen completes acquisition of RayThera

Biogen Completes Acquisition of RayThera Inc.

Aug 6, 2026, 6:15 PM EDT - 10 days ago

Biogen Completes Acquisition of RayThera Inc.

Biogen price target raised to $241 from $221 at Mizuho

2026-08-04T12:17:43.000Z - 13 days ago

Biogen price target raised to $241 from $221 at Mizuho

Biogen price target raised to $215 from $200 at Citi

2026-08-03T10:42:26.000Z - 14 days ago

Biogen price target raised to $215 from $200 at Citi

Biogen price target raised to $231 from $222 at Morgan Stanley

2026-07-30T16:11:19.000Z - 18 days ago

Biogen price target raised to $231 from $222 at Morgan Stanley

Biogen price target raised to $251 from $237 at H.C. Wainwright

2026-07-30T14:20:26.000Z - 18 days ago

Biogen price target raised to $251 from $237 at H.C. Wainwright

Biogen price target lowered to $240 from $242 at RBC Capital

2026-07-30T13:50:39.000Z - 18 days ago

Biogen price target lowered to $240 from $242 at RBC Capital

Biogen price target raised to $240 from $225 at UBS

2026-07-30T13:23:31.000Z - 18 days ago

Biogen price target raised to $240 from $225 at UBS

Biogen price target raised to $215 from $201 at Wedbush

2026-07-30T12:37:52.000Z - 18 days ago

Biogen price target raised to $215 from $201 at Wedbush

Biogen price target raised to $219 from $215 at BofA

2026-07-30T12:05:53.000Z - 18 days ago

Biogen price target raised to $219 from $215 at BofA

Biogen price target raised to $225 from $215 at TD Cowen

2026-07-30T11:32:48.000Z - 18 days ago

Biogen price target raised to $225 from $215 at TD Cowen

Biogen price target raised to $248 from $245 at Canaccord

2026-07-30T11:06:00.000Z - 18 days ago

Biogen price target raised to $248 from $245 at Canaccord

Biogen Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 19 days ago

Biogen Earnings Call Transcript: Q2 2026

Biogen Slides: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 19 days ago

Biogen Slides: Q2 2026

Biogen Earnings release: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 19 days ago

Biogen Earnings release: Q2 2026

Biogen Quarterly report: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 19 days ago

Biogen Quarterly report: Q2 2026

Biogen Cuts FY Adjusted View as Profit Declines

Jul 29, 2026, 6:23 AM EDT - 19 days ago

Biogen Cuts FY Adjusted View as Profit Declines

Biogen lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25

2026-07-29T10:16:45.000Z - 19 days ago

Biogen lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25

Biogen reports Q2 EPS $3.60, consensus $2.05

2026-07-29T10:11:40.000Z - 19 days ago

Biogen reports Q2 EPS $3.60, consensus $2.05

Biogen beats quarterly estimates as newer drugs fuel growth

Jul 29, 2026, 6:03 AM EDT - 19 days ago

Biogen beats quarterly estimates as newer drugs fuel growth

Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

Jul 29, 2026, 6:02 AM EDT - 19 days ago

Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

Biogen price target raised to $200 from $185 at Barclays

2026-07-29T09:10:46.000Z - 19 days ago

Biogen price target raised to $200 from $185 at Barclays

Biogen price target raised to $280 from $260 at Guggenheim

2026-07-21T12:06:03.000Z - 27 days ago

Biogen price target raised to $280 from $260 at Guggenheim

Biogen price target lowered to $215 from $217 at BofA

2026-07-21T11:25:27.000Z - 27 days ago

Biogen price target lowered to $215 from $217 at BofA

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Jul 16, 2026, 7:47 AM EDT - 4 weeks ago

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Biogen Appoints Michael J. Parini as Chief Legal Officer

Jul 15, 2026, 8:15 AM EDT - 4 weeks ago

Biogen Appoints Michael J. Parini as Chief Legal Officer

Biogen Transcript: Alzheimer’s Association International Conference (AAIC Meeting) 2026

Jul 14, 2026, 12:00 PM EDT - 4 weeks ago

Biogen Transcript: Alzheimer’s Association International Conference (AAIC Meeting) 2026

Biogen Slides: FY 2026

Jul 14, 2026, 12:00 PM EDT - 4 weeks ago

Biogen Slides: FY 2026

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Jul 14, 2026, 11:15 AM EDT - 4 weeks ago

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Biogen's Alzheimer's drug lowers toxic protein, but results were mixed

Jul 14, 2026, 9:18 AM EDT - 4 weeks ago

Biogen's Alzheimer's drug lowers toxic protein, but results were mixed

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

Jul 14, 2026, 9:15 AM EDT - 4 weeks ago

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

Jul 13, 2026, 5:36 PM EDT - 4 weeks ago

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

Jul 13, 2026, 3:02 PM EDT - 5 weeks ago

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details

Jul 13, 2026, 8:15 AM EDT - 5 weeks ago

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

Jul 12, 2026, 11:15 AM EDT - 5 weeks ago

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

Old cancer drug may help restore fertility for certain women

Jul 1, 2026, 7:18 AM EDT - 6 weeks ago

Old cancer drug may help restore fertility for certain women

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Jun 29, 2026, 6:59 AM EDT - 7 weeks ago

Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

Jun 26, 2026, 9:25 AM EDT - 7 weeks ago

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

APLS

Biogen to acquire RayThera for $1 billion

Jun 17, 2026, 7:10 PM EDT - 2 months ago

Biogen to acquire RayThera for $1 billion

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Jun 17, 2026, 6:59 PM EDT - 2 months ago

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 2 months ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 2 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY CVS PFE VZ

Biogen Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 2 months ago

Biogen Transcript: AGM 2026

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Jun 4, 2026, 7:30 AM EDT - 2 months ago

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Jun 4, 2026, 1:00 AM EDT - 2 months ago

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Jun 3, 2026, 7:30 AM EDT - 2 months ago

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 2 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

ABBV LLY ROP

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Jun 1, 2026, 1:30 AM EDT - 2 months ago

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

May 27, 2026, 2:27 AM EDT - 2 months ago

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

May 21, 2026, 6:17 PM EDT - 3 months ago

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

May 21, 2026, 6:00 PM EDT - 3 months ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

May 14, 2026, 12:10 PM EDT - 3 months ago

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

May 14, 2026, 9:07 AM EDT - 3 months ago

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

Biogen Completes Acquisition of Apellis Pharmaceuticals

May 14, 2026, 8:35 AM EDT - 3 months ago

Biogen Completes Acquisition of Apellis Pharmaceuticals

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

May 14, 2026, 7:03 AM EDT - 3 months ago

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

May 14, 2026, 6:59 AM EDT - 3 months ago

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

Biogen Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 3 months ago

Biogen Transcript: Bank of America Global Healthcare Conference 2026

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

May 8, 2026, 2:30 AM EDT - 3 months ago

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

May 7, 2026, 6:01 PM EDT - 3 months ago

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

APLS BFAM RELY TPH

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026, 4:01 PM EDT - 3 months ago

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

STOK

Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Earnings Call Transcript: Q1 2026

Biogen Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Slides: Q1 2026

Biogen Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Earnings release: Q1 2026

Biogen Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Biogen Quarterly report: Q1 2026

Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 7:02 AM EDT - 3 months ago

Biogen Lowers 2026 Earnings Outlook

Biogen cuts annual profit forecast on acquisition-related charges

Apr 29, 2026, 6:07 AM EDT - 3 months ago

Biogen cuts annual profit forecast on acquisition-related charges

Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Biogen Proxy statement: Proxy filing

Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Biogen Proxy statement: Proxy filing

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Apr 20, 2026, 9:02 AM EDT - 4 months ago

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

ksoption
ksoption Aug. 16 at 4:16 PM
$CBOE $PM $HON $BIIB
0 · Reply
SnowyDingo
SnowyDingo Aug. 15 at 5:43 PM
$NAGE CEO spent the earnings call seeding a takeout narrative. 4 buyer universes: 🛒 CPG (Thorne/PG $3.8B comp) → $NSRGY (Nestlé Health Science) 💄 Beauty ("2 global skincare cos") → $LRLCY (L'Oréal) 💊 Pharma (Reata/ $7.3B comp) → $BIIB, for NB4168 📱 Telehealth → $HIMS But: comp gated on $15 PSUs, so he's incentivized to talk his book. "In discussions" ≠ deal. No name, no LOI, no timeline. Real tell = a signed exclusive skincare supply deal w/ a named $LRLCY-tier buyer. Until then it's CEO optionality, not a catalyst
1 · Reply
ksoption
ksoption Aug. 15 at 1:16 AM
$NBIS $C $BIIB 🤞
0 · Reply
GoforProMIS
GoforProMIS Aug. 14 at 2:13 PM
$PMN PT Raised to $100 at Guggenheim Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drug's efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer's. If PMN shows the potential to be safer than existing treatments $LLY $BIIB. FDA views it ethical imperative to expedite the approval process through fast-track programs. https://www.streetinsider.com/dr/news.php?id=26925256&gfv=1
0 · Reply
11thestate
11thestate Aug. 14 at 1:47 PM
There’s another $BIIB investor settlement to know about. The settlement centers on claims that Biogen misled investors about aducanumab’s clinical trial data and why the ENGAGE study failed. After FDA briefing materials raised concerns in 2020, the FDA Advisory Committee voted 10-0 against the drug’s effectiveness, and $BIIB fell 28%. This case covers purchases between 2019 and 2020. If you weren't eligible for the other Biogen case, you may want to check this one, since the class period is different and extends further back. Check if your eligible and file a claim: https://11th.com/cases/biogen-investor-settlement
0 · Reply
vjtweet
vjtweet Aug. 12 at 7:24 PM
$BIIB new long. No rush.. hold for many months.
0 · Reply
11thestate
11thestate Aug. 10 at 1:46 PM
Imagine buying $BIIB at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $BIIB investors out there, we’ve got some important news: a $18.9 million investor settlement is now open for claims from shareholders who purchased shares in 2021 The deadline is next months, you can check if you’re eligible and claim your share: https://11th.com/cases/biib-investor-settlement
0 · Reply
Fangster1
Fangster1 Aug. 9 at 7:14 PM
$BIIB $GANX $JAZZ Very good give and take to this thread. I’ll never pretend to fully understand the science but I do understand statements made by the company. IMO they have a good idea where the 270 stands. If the 270 is a known negative, I would think some level of disclosure would be necessary after the company speak. As an investor, no issue waiting for the 360. If the 360 plays out, we’re solid gold with diamond hands. We’ll see!
1 · Reply
Jwa68
Jwa68 Aug. 9 at 1:02 AM
$GANX Khalid and Gene are very wisely beginning to position Gain as a platform company, versus a single drug company, with a vast multi target franchise opportunity in neurodegeneration. With Magellan capable of generating an endless organic pipeline of additional molecules which may be advanced to the clinic, all building upon what they have learned from GT-00287. While we will never get there unfortunately, this is similar to how $BIIB (Biogen) was started way back when and trading at just a couple dollars a share, along with $JAZZ. Ironically, Gene was one of the first analysts to initiate and recommend both names in their infancy, early on on his career as an analyst.
2 · Reply
GoforProMIS
GoforProMIS Aug. 7 at 5:48 PM
$PMN $LLY $BIIB $RHHBY The real jackpot: PMN267 + PMN442 ProMIS describes three key antibody programs: PMN310 → Alzheimer's disease / Amyloid-ß oligomers => PMN310 potential $5-10 bn * PMN267 → ALS / misfolded TDP-43 => PMN267 potential $1-3 bn * PMN442 → Parkinson's disease, MSA, => PMN442 potential $1-3 bn and other synucleinopathies Other Platforms potential $0,5-2 bn means in total range from 7.5-18 bn with a potential Share price of => $405 to $970 This is not pure fantasy.
0 · Reply
jewell69
jewell69 Aug. 6 at 6:04 PM
8/6 2:01 pm edt re-entry $BIIB Biogen, Inc Status Filled at $205.504 Symbol BIIB Symbol Description BIOGEN INC COM USD0.0005 Action Buy Quantity 20 Shares
0 · Reply
MarketIntel_
MarketIntel_ Aug. 5 at 2:31 PM
Today's Trading Watchlist $AVAV - Hold $170, targets $184 and $193. $AVGO - Trigger over $422, target $440. $BB - Trigger over $8.95, target $10. $BE - Trigger over $236, targets $254 and $268. $BIIB - Trigger over $209, target $216. Keeping these names on radar as price action decides the next move. Focus is on confirmation, not chasing.
1 · Reply
BrendaSaxe1022
BrendaSaxe1022 Aug. 5 at 6:48 AM
$CFG $GFI $BIIB $RDDT $ILMN Citizens Financial strengthens banking operations, Gold Fields benefits from higher gold prices, Biogen advances neurological therapies, Reddit continues improving advertising monetization, and Illumina leads genomic sequencing.
0 · Reply
GabrielBarrett973
GabrielBarrett973 Aug. 5 at 5:32 AM
$CNC $LVS $AEE $SUNB $BIIB Centene benefits from managed healthcare growth, Las Vegas Sands gains from casino demand, Ameren provides regulated utility exposure, SUNB remains execution-driven, and Biogen advances neurological therapies.
0 · Reply
jdlman
jdlman Aug. 4 at 4:36 PM
$INCY $BIIB ..shut up josh brown .. always says it after the fact
1 · Reply
Quantumup
Quantumup Aug. 4 at 11:37 AM
Canaccord Genuity y'day⬇️ $STOK to $58 from $60 and reiterated Buy after STOK reported its 2Q26 results. $BIIB PRAX DRUG HLUBF HLBBF $IONS HRMY OVID SUPN UCBJY JAZZ Here's what Canaccord Genuity said in its note to investors: https://x.com/Quantumup1/status/2084604516561756445?s=20
0 · Reply
IN0V8
IN0V8 Aug. 3 at 3:47 PM
$BIIB Citigroup raises target price to $215 from $200
0 · Reply
AnthonyCottrell683
AnthonyCottrell683 Aug. 3 at 2:47 PM
$CNC $LVS $AEE $SUNB $BIIB Centene benefits from managed healthcare growth, Las Vegas Sands gains from casino demand, Ameren provides regulated utility exposure, SUNB remains execution-driven, and Biogen advances neurological therapies.
0 · Reply
flychicken1991
flychicken1991 Aug. 1 at 4:07 PM
$BIIB Positive (78%): BIIB’s stock price is likely pushed higher by the reported revenue beat and adjusted EPS surprise, although the incremental move could be limited if the market already reacted to the original earnings release. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/a76cfb17fb16349b?utm_source=stocktwits&utm_medium=story_url
0 · Reply
GoforProMIS
GoforProMIS Jul. 30 at 11:28 AM
$PMN is it $BIIB $LLY or is it $RHHBY for Alzheimer Disease ?
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 7:54 PM
upgrade scoreboard $BIIB $MU $INTC $AAL drew fresh bullish calls, but only one paired the upgrade with real volume confirmation. read the full breakdown. https://stocksrunner.com/news/2026-07-29-wall-street-analyst-upgrades-to-watch
1 · Reply
notreload_ai
notreload_ai Jul. 29 at 3:45 PM
$BIIB reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%. https://notreload.xyz/xy/biogen-beats-q2-estimates-as-newer-drugs-drive-growth/
0 · Reply